| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | PROTEGO BIOPHARMA, INC. | 10945 VISTA SORRENTO PKWY | SAN DIEGO | CA | 92130-8757 | SAN DIEGO | USA | U44NS114151 | Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR) | 000 | 3 | NIH | 12/4/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $700,619 ) |
| | 2023 | 2023 | PROTEGO BIOPHARMA, INC. | 10945 VISTA SORRENTO PKWY | SAN DIEGO | CA | 92130-8757 | SAN DIEGO | USA | U44NS114151 | Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR) | 000 | 3 | NIH | 11/24/2022 | $700,619 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | PROTEGO BIOPHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS114151 | Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR) | 001 | 2 | NIH | 8/25/2022 | $0 |
| | 2022 | 2020 | PROTEGO BIOPHARMA, INC. | 10945 VISTA SORRENTO PKWY | SAN DIEGO | CA | 92130-8757 | SAN DIEGO | USA | U44NS114151 | Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR) | 000 | 1 | NIH | 3/24/2022 | $0 |
| | 2022 | 2020 | PROTEGO BIOPHARMA, INC. | 10945 VISTA SORRENTO PKWY | SAN DIEGO | CA | 92130-8757 | SAN DIEGO | USA | R43NS108814 | Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses | 000 | 2 | NIH | 3/16/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,368,143 ) |
| | 2021 | 2021 | PROTEGO BIOPHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS114151 | Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR) | 000 | 2 | NIH | 4/29/2021 | $1,368,143 |
|
| Issue Date FY: 2020 ( Subtotal = $910,042 ) |
| | 2020 | 2020 | PROTEGO BIOPHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS108814 | Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses | 000 | 2 | NIH | 8/4/2020 | $210,042 |
| | 2020 | 2020 | PROTEGO BIOPHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | U44NS114151 | Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR) | 000 | 1 | NIH | 4/7/2020 | $700,000 |
| | 2020 | 2018 | PROTEGO BIOPHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43TR002436 | Development of an early diagnostic and biomarker of treatment response for TTR amyloidoses (ATTR) | 000 | 1 | NIH | 1/23/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $419,185 ) |
| | 2019 | 2019 | MISFOLDING DIAGNOSTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS108814 | Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses | 000 | 1 | NIH | 9/16/2019 | $419,185 |
|
| Issue Date FY: 2018 ( Subtotal = $325,000 ) |
| | 2018 | 2018 | MISFOLDING DIAGNOSTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43TR002436 | Development of an early diagnostic and biomarker of treatment response for TTR amyloidoses (ATTR) | 000 | 1 | NIH | 2/27/2018 | $325,000 |
|
|
